Fig. 5. Association between the Blue_response signature score and the rate of pathological complete response (pCR) in TMO-based HER2-positive breast cancer cohorts treated with a combination of chemotherapy and anti-HER2 targeted therapy.
      We developed an algorithm to calculate absolute Blue_response signature scores independently of cohort-wide data. This approach enables direct comparison of scores across TMO arrays (comprising nine cohorts in this study) and allows for the calculation of signature scores for newly added individual samples. All samples were stratified into three groups based on their signature scores: low (≤30), medium (30–60), and high (>60). The pCR rates were then compared among these groups.  Data for the remaining nine non-TMO HER2-positive breast cancer cohorts is presented in the next figure.
